Hepion pharmaceuticals announces participation in the h.c. wainwright bioconnect conference

Edison, n.j., jan. 05, 2022 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“nash”) and other liver diseases, today announced that it will participate in the h.c. wainwright bioconnect conference, to be held virtually january 10-13, 2022.
HEPA Ratings Summary
HEPA Quant Ranking